Kura Oncology publishes ziftomenib combination study in Blood journal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- S&P 500, Nasdaq drop as tech megacap declines outweigh upbeat Micron forecast
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
June 2, 2026 8:32 AM EDT87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose
Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months
Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure
Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed
SAN DIEGO and TOKYO, June 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, Kura) and Kyowa Kirin Co., Ltd.... More
